It uses CRISPR–AsCas12a to edit the HBG1 and HBG2 promoters for autologous HSPC transplantation into patients with severe SCD and β‐thalassemia (NCT04853576). The gene discussed is HBG1; the disease is Schnyder corneal dystrophy.